Bridging the gap: Multi‐omics profiling of brain tissue in Alzheimer’s disease and older controls in multi‐ethnic populations

by Clinical Neuropsychologist | Saturday, August 31, 2024 | Dementia

Abstract INTRODUCTION Multi-omics studies in Alzheimer’s disease (AD) revealed many potential disease pathways and therapeutic targets. Despite their promise of precision medicine, these studies lacked Black Americans (BA) and Latin Americans (LA), who are...

Ischemic stroke associated with amyloid‐related imaging abnormalities in a patient treated with lecanemab

by Clinical Neuropsychologist | Saturday, August 31, 2024 | Dementia

Abstract INTRODUCTION Anti-amyloid antibody therapies such as lecanemab are increasingly being used to treat Alzheimer’s disease (AD). These therapies are associated with a high rate of amyloid-related imaging abnormalities (ARIA). METHODS We review the case...

Cellular prion protein acts as mediator of amyloid beta uptake by caveolin‐1 causing cellular dysfunctions in vitro and in vivo

by Clinical Neuropsychologist | Friday, August 30, 2024 | Dementia

Abstract INTRODUCTION Cellular prion protein (PrPC) was implicated in amyloid beta (Aβ)-induced toxicity in Alzheimer’s disease (AD), but the precise molecular mechanisms involved in this process are unclear. METHODS Double transgenic mice were generated by...

The impact of social isolation and loneliness on the well-being of carers of a person with dementia in aotearoa New Zealand

by Clinical Neuropsychologist | Friday, August 30, 2024 | Dementia

Dementia, Volume 24, Issue 2, Page 235-248, February 2025. Dementia is a leading cause of disability, and as the population ages, there will be a greater need for friends and family to care for people with Dementia. Unfortunately, informal care for a person with...

My experience of person-centered and personalized care in early-stage primary progressive aphasia

by Clinical Neuropsychologist | Friday, August 30, 2024 | Dementia

Dementia, Volume 24, Issue 3, Page 353-367, April 2025. Primary progressive aphasia (PPA) is a neurodegenerative brain disorder characterized by declining language ability. It is a rare, often young-onset dementia with a devastating impact on the work and personal...

Blood‐derived microRNAs are related to cognitive domains in the general population

by Clinical Neuropsychologist | Friday, August 30, 2024 | Dementia

Abstract INTRODUCTION Blood-derived microRNAs (miRNAs) are potential candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel miRNAs associated with cognitive domains, including...